证券代码：688298 证券简称：东方生物 公告编号：2025-047 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 一、回购股份的基本情况 浙江东方基因生物制品股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开第三届董事会第十三次会议，审议通过了《关于以集中竞价交易方式回购 公司股份的方案》，同意公司以自有资金或自筹资金（含股票回购专项贷款资金等） 通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币 普通股（A 股）股票，本次回购的股份将用于维护公司价值及股东权益，回购价格 不超过人民币 32.44 元/股（含），回购资金总额不低于人民币 2,500 ...

表决情况：本议案有效表决票 6 票，同意 6 票、反对 0 票、弃权 0 票。 本议案尚需提交股东会审议通过。 证券代码：688298 证券简称：东方生物 公告编号：2025-043 浙江东方基因生物制品股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"公司"）第三届董事会第 十四次会议于 2025 年 8 月 16 日以电子邮件及通讯形式发出会议通知，于 2025 年 8 月 28 日上午 10:00 在公司会议室以现场会议加通讯表决的方式召开。会议 应出席董事 6 名，实到出席董事 6 名。会议召开符合法律法规、《公司法》及《公 司章程》的相关规定。 会议由董事长方剑秋先生主持召开，全体与会董事经认真审议和表决，形成 以下决议： 表决情况：本议案有效表决票 6 票，同意 6 票、反对 0 票、弃权 0 票。 公司独立董事已召开专门会议审议通过半年度报告中的财务信息，审计委员 会已审议通过本议案。 具体内容详见公司于同日在上海证券交易所网站(http://www.s ...

浙江东方基因生物制品股份有限公司（以下简称"公司"）第三届监事会第 十三次会议于 2025 年 8 月 16 日以电子邮件及通讯形式发出会议通知，于 2025 年 8 月 28 日下午 14：00 在公司会议室以现场会议方式召开。会议应出席监事 3 名，实到出席监事 3 名。会议召开符合法律法规、《公司法》及《公司章程》的 相关规定。 会议由监事方晓萍女士主持召开，全体与会监事经认真审议和表决，形成以 下决议： 监事会认为：董事会编制和审议公司《2025 年半年度报告》的程序符合法 律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。表决结果：本 议案有效表决票 3 票，3 票同意，0 票反对，0 票弃权。 具体内容详见公司于同日在上海证券交易所网站(http://www.sse.com.cn) 披露的《2025 年半年度报告》及《2025 年半年度报告摘要》。 表决结果：本议案有效表决票 3 票，3 票同意，0 票反对，0 票弃权。 具体内容详见公司于同日在上海证券交易所网站(http://www.sse.com.cn) 披露的《 ...

Meeting Information - The shareholder meeting is scheduled for September 15, 2025, at 10:00 AM [1] - The meeting will be held at the conference room of Zhejiang Orient Gene Biotech Co., Ltd. in Anji County, Huzhou City, Zhejiang Province [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - The network voting will be available from 9:15 AM to 3:00 PM on the day of the meeting [1] - Shareholders can vote via the trading system or the internet voting platform [4] - Duplicate votes through different methods will be counted based on the first vote cast [4] Shareholder Eligibility - Shareholders registered by the close of trading on September 8, 2025, are eligible to attend the meeting [5] - Shareholders can appoint proxies to attend and vote on their behalf [5] Registration Process - Registration for the meeting can be done on-site or through mail, fax, or email for distant shareholders [6] - Specific documentation is required for different types of shareholders, including personal identification and proof of shareholding [6] Other Meeting Details - The meeting is expected to last half a day, and attendees are responsible for their own travel and accommodation expenses [6] - Attendees should arrive at least 30 minutes early for registration [6]

Group 1 - The company has been expanding its domestic and international production capacity, sales networks, and product lines through acquisitions and new projects, which has led to increased management, research and development, and sales expenses, impacting short-term operating performance [1][3][4] - The company faces potential risks of losses in overall operating performance by 2025 due to high costs associated with new projects and acquisitions [3][4] - The company is actively responding to global tariff changes that may affect its export business, particularly in the US and Europe, by optimizing market layouts and reducing product costs [3][4] Group 2 - The company is involved in a significant contract dispute in the US, which has not yet impacted its 2025 financial results, and it is taking legal action to protect its interests [3][4][5] - The company has submitted a defense in the ongoing lawsuit and has temporarily withdrawn a related civil suit in China while retaining the right to pursue it later [4][5][6] Group 3 - The company plans to hold a half-year performance briefing on September 11, 2025, to address investor concerns and provide insights into its financial status [7][8][9] - The company will also hold its first extraordinary general meeting of 2025 on September 15, 2025, to discuss various resolutions, including the cancellation of the supervisory board [14][15][16] Group 4 - The company reported a total fundraising amount of 637.5 million yuan from its initial public offering, with a net amount of 550.82 million yuan after expenses [37][38] - As of June 30, 2025, the company has utilized 10.11 million yuan of the raised funds for investment projects, with a remaining balance of 61.85 million yuan [38][41]

Core Points - The company announced the resignation of Mr. Fang Xincheng from the board of directors and the audit committee due to personal reasons [1] - The resignation will not affect the minimum number of directors required by law and will not disrupt the normal operation of the board [1] - The company expressed gratitude for Mr. Fang's contributions during his tenure [1] Summary by Sections Resignation Announcement - Mr. Fang Xincheng submitted a written resignation report to the board [1] - His resignation is effective immediately upon delivery to the board [1] Impact on Company Operations - The resignation will not lead to a decrease in the number of directors below the legal minimum [1] - The normal functioning of the board will remain unaffected [1] Acknowledgment of Contributions - The company and the board expressed sincere thanks for Mr. Fang's diligent work and contributions to the company's development [1]

格隆汇8月28日丨东方生物(688298.SH)发布中报，2025上半年实现营业总收入4.03亿元，同比下降 3.62%；归属母公司股东净利润-1.63亿元，较上年同期亏损增加1149.03万元；基本每股收益为-0.84元。 ...

Group 1 - The company, Oriental Bio, announced the resignation of Mr. Fang Xincheng from its board of directors and audit committee due to personal reasons, effective immediately upon receipt of the resignation report [1] - The resignation will not affect the minimum number of directors required by law, ensuring the normal operation of the board [1] - For the fiscal year 2024, the company's revenue composition is 97.99% from the in vitro diagnostics industry and 2.01% from other businesses [1] Group 2 - As of the report, Oriental Bio has a market capitalization of 5.5 billion yuan [1]

证券日报网讯8月28日晚间，东方生物发布公告称，公司董事会于近日收到方新成先生递交的书面辞职 报告，因个人原因申请辞去公司第三届董事会董事、审计委员会委员职务，辞职后将不再担任公司职 务。 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-039 浙江东方基因生物制品股份有限公司 关于董事辞职的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告！ 浙江东方基因生物制品股份有限公司 董 事 会 2025 年 8 月 29 日 浙江东方基因生物制品股份有限公司（以下简称"公司"）董事会于近日收 到方新成先生递交的书面辞职报告，因个人原因申请辞去公司第三届董事会董事、 审计委员会委员职务，辞职后将不再担任公司职务。根据《中华人民共和国公司 法》《公司章程》等有关规定，方新成先生辞去公司董事职务不会导致公司董事 会人数低于法定最低人数，不会影响公司董事会正常运行，辞职报告自送达公司 董事会之日起生效。 方新成先生在担任公司董事、董事会审计委员会委员期间恪尽职守、勤勉尽 责，为公司发展做出了卓越的贡献，公司及公司董事会真诚感谢方新成先生的辛 勤付出。 ...